Analysts Offer Predictions for Prime Medicine Q1 Earnings

Prime Medicine, Inc. (NYSE:PRME - Free Report) - Equities researchers at Wedbush issued their Q1 2026 earnings per share estimates for Prime Medicine in a note issued to investors on Thursday, May 8th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($0.38) per share for the quarter. Wedbush currently has a "Outperform" rating and a $13.00 target price on the stock. The consensus estimate for Prime Medicine's current full-year earnings is ($1.68) per share. Wedbush also issued estimates for Prime Medicine's Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.36) EPS and Q4 2026 earnings at ($0.35) EPS.

Other equities analysts have also issued reports about the company. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Prime Medicine in a research note on Wednesday, March 19th. StockNews.com upgraded Prime Medicine to a "sell" rating in a research note on Tuesday, February 11th. Finally, Chardan Capital upped their target price on Prime Medicine from $15.00 to $16.00 and gave the company a "buy" rating in a research note on Thursday, March 20th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $13.14.

Prime Medicine Stock Down 1.5%

Shares of NYSE:PRME opened at $1.30 on Monday. Prime Medicine has a 52-week low of $1.12 and a 52-week high of $8.27. The stock's fifty day simple moving average is $1.66 and its 200-day simple moving average is $2.61. The company has a market capitalization of $170.51 million, a P/E ratio of -0.63 and a beta of 1.90.

Prime Medicine (NYSE:PRME - Get Free Report) last issued its quarterly earnings data on Friday, March 7th. The company reported ($1.65) earnings per share (EPS) for the quarter. During the same quarter last year, the firm posted ($2.18) earnings per share.

Institutional Investors Weigh In On Prime Medicine

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. increased its stake in Prime Medicine by 4.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,977,828 shares of the company's stock worth $11,616,000 after acquiring an additional 170,541 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Prime Medicine by 2.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,584,476 shares of the company's stock worth $4,628,000 after acquiring an additional 38,515 shares during the last quarter. Geode Capital Management LLC increased its stake in Prime Medicine by 7.9% during the fourth quarter. Geode Capital Management LLC now owns 1,467,606 shares of the company's stock worth $4,287,000 after acquiring an additional 107,627 shares during the last quarter. Westwood Holdings Group Inc. increased its stake in Prime Medicine by 96.5% during the fourth quarter. Westwood Holdings Group Inc. now owns 883,129 shares of the company's stock worth $2,579,000 after acquiring an additional 433,653 shares during the last quarter. Finally, Greenwich Wealth Management LLC increased its stake in Prime Medicine by 5.6% during the fourth quarter. Greenwich Wealth Management LLC now owns 774,001 shares of the company's stock worth $2,260,000 after acquiring an additional 41,000 shares during the last quarter. 70.37% of the stock is currently owned by institutional investors and hedge funds.

About Prime Medicine

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.